Research and development, or R&D, is the lifeblood of the biopharmaceutical industry.
According to the Congressional Budget Office, biopharma companies spend 25% or more of their revenues on R&D of new drugs and products to help save lives.
But startup biopharma companies face a problem: Most don’t have the revenue to reinvest in R&D. That leaves them to look for new capital to fund development.
That’s where this power stock comes in…
The post Biopharma Startups Need $$$ for R&D: That’s Where This Power Stock Comes In originally appeared at Money & Markets.